A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

• Status: Not yet recruiting
• Trial end date: 2037-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oncternal Therapeutics, Inc

Criteria

Key Inclusion Criteria:

• Over 18 years old

• Histologically confirmed aggressive B-cell NHL, including:

• MCL, with diagnosis confirmed by cyclin D1 overexpression or evidence of t (11;14) translocation

• LBCL, including:

• DLBCL NOS

• Primary mediastinal LBCL

• High-grade BCL

• DLBCL arising from follicular lymphoma

• Follicular lymphoma grade 3B

• Richter's syndrome

• Availability of archival tissue for immunohistology, or willing to undergo baseline biopsy if not available

• R/R with no available therapy. Subject must have:

• Received prior systemic therapy that has included an alkylating agent, anthracycline, and an anti-CD20 mAb

• Received and progressed after autologous hematopoietic stem cell transplant (HSCT) or is ineligible for or has refused to receive HSCT

• Received prior approved CD19 CAR T-cell therapy or is ineligible for or has refused CD19 CAR-T

• Minimum washout period between previous systemic therapy and leukapheresis includes:

• Chemotherapy: at least 14 days or 5 half-lives, whichever is shorter

• Autologous HSCT: at least 3 months

• CD19 CAR T-cell therapy: at least 6 months

• ≥1 measurable lesion per Lugano criteria (Cheson, 2014)

• Subject has Fluorodeoxyglucose (FDG)-avid disease.

• Subject has an ECOG performance status of 0 or 1.

• Subject has adequate organ function:

• ALC ≥100/uL

• ANC ≥1000/uL (≥500/uL if due to lymphoma; growth factors allowed)

• Hgb ≥8 g/dL (transfusion allowed)

• Platelets ≥75,000/uL (≥50,000/uL if due to lymphoma; transfusion allowed)

• CrCL ≥50 ml/min; AST/ALT ≤2.5x ULN, T. bili ≤1.5 mg/dl (except Gilbert's)

• EF ≥50% by ECHO/MUGA; NCS ECG, NCS pleural effusion; O2 sat >92%

• Subject has an estimated life expectancy of >12 weeks

Key Exclusion Criteria:

• Prior ROR1-targeted therapy

• Current or anticipated systemic immunosuppressive therapy (e.g., prednisone >5 mg) from LD chemo until Day 28 post ONCT-808 dosing

• If receiving anticoagulation therapy, subject is unable to hold therapy for 3 days prior and 28 days following ONCT-808 administration

• Known CNS involvement by malignancy within 6 months

• H/o or current CNS disorder (e.g., seizure, CVA, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome or any autoimmune disease with CNS involvement) within 6 months of study entry

• Clinically significant cardiovascular disease (e.g., MI, UA, CABG, or CHF grade ≥2 NYHA within 12 months of planned ONCT-808 dosing) or serious arrhythmia requiring medication

• Evidence of HIV infection or active HBV, HCV

• Systemic fungal infection requiring medication in the last 12 months

• H/o Covid-19 infection with residual lung infiltrate/fibrosis

• H/o other malignancy except non-melanoma skin cancer or carcinoma in situ not in remission for ≥2 years

• H/o autoimmune disease resulting in end organ injury or require systemic immunosuppression within last 2 years

• H/o allogeneic HSCT or organ transplant